Table 1.

Demographics and key baseline characteristics

All patients (N = 40)*
Sex, n (%)
    Women23 (57.5)
    Men17 (42.5)
Race, n (%)
    White35 (87.5)
    Black3 (7.5)
    Hispanic or Latino1 (2.5)
    American Indian or Alaskan Native1 (2.5)
Age (y)
    Median59
    Range24-78
ECOG performance status, n (%)
    024 (60)
    114 (35)
    21 (3)
    31 (3)
Primary tumor type, n (%)
    Other14 (35)
    Renal cell5 (13)
    Breast4 (10)
    Ovarian4 (10)
    Melanoma3 (8)
    Non–small cell lung3 (8)
    Soft tissue sarcoma3 (8)
    Pancreatic2 (5)
    Uterine2 (5)
Prior radiotherapy, n (%)22 (55)
Regimens of prior therapy, n (%)
    06 (15)
    15 (13)
    26 (15)
    ≥323 (58)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • *Safety analysis set includes patients who received one or more dose of AMG 102.

  • Patient was enrolled per protocol-specified eligibility criteria, but her condition deteriorated before the first dose of AMG 102. The patient was issued a postenrollment eligibility deviation and was removed from the study on day 15 as a result of progressive disease.

  • Includes two patients with hepatocellular carcinoma and one each with bladder, glioblastoma multiforme, colon, gallbladder, lung, lymph node metastasis, neuroendocrine, peritoneal adenocarcinoma, perivascular epithelioid, salivary gland, small bowel, and stomach cancers.